SAN DIEGO, April 11, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Ocugen, Inc. (NASDAQ: OCGN) securities between May 8, 2020 and April 1, 2024. Ocugen, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to cure blindness diseases.

For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.

The Allegations: Robbins LLP is Investigating the Allegations that Ocugen, Inc. (OCGN) Lacked Proper Internal Controls Over Financial Reporting

According to the complaint, during the class period, defendants failed to disclose that Ocugen’s financial statements from May 8, 2020 to the present were materially misstated and Ocugen did not have adequate internal controls.

Plaintiff alleges that on April 1, 2024, Ocugen announced that "the Audit Committee of the Board of Directors (the “Audit Committee”), based on the recommendation of management and after consultation with EY, concluded that the Company’s previously-issued audited consolidated financial statements for each fiscal year beginning January 1, 2020 and its previously-issued unaudited interim condensed consolidated financial statements for each of the first three quarters in such years, as well as the associated earnings releases and investor presentations or other communications describing such financial statements, were materially misstated and, accordingly, should no longer be relied upon.

The Company intends to restate its consolidated financial statements as of and for the year ended December 31, 2022, in connection with the filing of its 2023 Form 10-K. Similarly, the Company will include restated unaudited financial information for each of the first three quarters of 2023 and 2022 in its 2023 Form 10-K (each such annual and quarterly period to be restated, a “Restated Period”)."

On this news, Ocugen's stock price fell $0.16 per share, or over 10%, to close at $1.38 per share on April 2, 2024, damaging investors.

What Now: You may be eligible to participate in the class action against Ocugen, Inc. Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by June 10, 2024. A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery. If you choose to take no action, you can remain an absent class member. For more information, click here.

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.  

About Robbins LLP: Some law firms issuing releases about this matter do not actually litigate securities class actions; Robbins LLP does. A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. Since our inception, we have obtained over $1 billion for shareholders.

To be notified if a class action against Ocugen, Inc. Luna Innovations Incorporated settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/16e14ccc-69f4-4cc4-ba43-b253d5203b9e